Vindesine-Epirubicin versus Vindesine-Mitoxantrone in Metastatic Breast Cancer
H. Hausmaninger(Unfallkrankenhaus Salzburg), A Neiss, Renate Haidinger, L. Schiller, M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Fridrik, R. Kienzer(Kaiser-Franz-Josef-Spital), H. Samonigg, P. Sevelda, G.G. Steger(National Cancer Center), D. Manfreda, G. Michlmayr(Ordensklinikum Linz Barmherzige Schwestern), W. Hehenwarter
Cited by 8
Related Papers
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|PubMed|1996|388
Clinical multidrug resistance in cancer: A multifactorial problem
|European Journal of Cancer|1996|178